ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
95,502.68
-1.75%
S&P 500
5,930.85
1.09%
Dow Jones
42,840.26
1.18%
US Dollar vs Yen
156.445
0.00%
Brent Oil
72.72
0.00%
Registration Strip Icon for monitor ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ

  6. Spyre Therapeutics Inc (SYRE) 銘柄情報

Spyre Therapeutics Inc

Spyre Therapeutics Inc (SYRE)

NASDAQ
23.86
0.73
(3.16%)
終了 12月23日 6:00AM
15分遅延
23.86
-0.03
(-0.13%)
取引時間後: 6:06AM
15分遅延

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

主要統計と詳細

通貨
23.86
買値
20.36
売値
37.00
出来高
1,259,573
22.62 日の範囲 24.88
15.41 52 週間の範囲 47.97
時価総額
1.227B
前日終値
23.13
始値
22.90
時刻
4370
@
23.86
(priorref)
最終取引時間
財務取引量
US$ 29,755,850
VWAP
23.6238
平均取引量 (3 か月)
524,978
発行済株式数
51,431,220
配当利回り
-
PER
-3.63
1 株当たり利益 (EPS)
-6.59
歳入
886k
純利益
-338.79M

Spyre Therapeutics Inc について

Aeglea BioTherapeutics Inc is a clinical-stage biotechnology company. It designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in an e... Aeglea BioTherapeutics Inc is a clinical-stage biotechnology company. It designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in an early clinical development stage. 詳細を表示

セクター
Pharmaceutical Preparations
業界
Pharmaceutical Preparations
ウェブサイト
www.spyre.com
本社
Wilmington, Delaware, USA
設立
-
Spyre Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the ナスダック市場 with ticker SYRE. The last closing price for Spyre Therapeutics was US$23.13. Over the last year, Spyre Therapeutics shares have traded in a share price range of US$ 15.41 to US$ 47.97.

Spyre Therapeutics currently has 51,431,220 shares in issue. The market capitalisation of Spyre Therapeutics is US$1.19 billion. Spyre Therapeutics has a price to earnings ratio (PE ratio) of -3.63.

SYRE 最新ニュース

その他のニュース

Spyre Therapeutics Added to the Nasdaq Biotechnology Index

Spyre Therapeutics Added to the Nasdaq Biotechnology Index PR Newswire WALTHAM, Mass., Dec. 18, 2024 WALTHAM, Mass., Dec. 18, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a...

2024年12月18日
PR Newswire (US)

Spyre Therapeutics Announces Grants of Inducement Awards

Spyre Therapeutics Announces Grants of Inducement Awards PR Newswire WALTHAM, Mass., Dec. 2, 2024 WALTHAM, Mass., Dec. 2, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the...

2024年12月3日
PR Newswire (US)

Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies

Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies PR Newswire WALTHAM, Mass., Dec. 2, 2024 Spyre is concurrently advancing...

2024年12月2日
PR Newswire (US)

Spyre Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference

Spyre Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference PR Newswire WALTHAM, Mass., Nov. 25, 2024 WALTHAM, Mass., Nov. 25, 2024 /PRNewswire/ -- Spyre Therapeutics...

2024年11月26日
PR Newswire (US)

Form 8-K - Current report

2024年11月20日
Edgar (US Regulatory)

Form 424B5 - Prospectus [Rule 424(b)(5)]

2024年11月20日
Edgar (US Regulatory)

Spyre Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock

Spyre Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock PR Newswire WALTHAM, Mass., Nov. 18, 2024 WALTHAM, Mass., Nov. 18, 2024 /PRNewswire/ -- Spyre Therapeutics...

2024年11月19日
PR Newswire (US)

Form 424B5 - Prospectus [Rule 424(b)(5)]

2024年11月19日
Edgar (US Regulatory)

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants PR Newswire WALTHAM, Mass., Nov. 18, 2024 WALTHAM, Mass., Nov. 18, 2024 /PRNewswire/ -- Spyre...

2024年11月19日
PR Newswire (US)

Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]

2024年11月19日
Edgar (US Regulatory)
期間 †前日比前日比 %始値高値安値平均出来高VWAP
1-0.51-2.0927369716924.3725.7722.5753033224.09771236CS
4-2.98-11.102831594626.8429.0622.5753352326.22322071CS
12-5.45-18.59433640429.3140.122.5752497829.66930502CS
26-1.89-7.3398058252425.7540.122.1959143628.00736346CS
526.7739.613809245217.0947.9715.4151278829.64995766CS
15613.05120.72155411710.8147.9710.4249203629.40829318CS
26013.05120.72155411710.8147.9710.4249203629.40829318CS

SYRE - Frequently Asked Questions (FAQ)

What is the current Spyre Therapeutics share price?
The current share price of Spyre Therapeutics is US$ 23.86
How many Spyre Therapeutics shares are in issue?
Spyre Therapeutics has 51,431,220 shares in issue
What is the market cap of Spyre Therapeutics?
The market capitalisation of Spyre Therapeutics is USD 1.19B
What is the 1 year trading range for Spyre Therapeutics share price?
Spyre Therapeutics has traded in the range of US$ 15.41 to US$ 47.97 during the past year
What is the PE ratio of Spyre Therapeutics?
The price to earnings ratio of Spyre Therapeutics is -3.63
What is the cash to sales ratio of Spyre Therapeutics?
The cash to sales ratio of Spyre Therapeutics is 1.39k
What is the reporting currency for Spyre Therapeutics?
Spyre Therapeutics reports financial results in USD
What is the latest annual turnover for Spyre Therapeutics?
The latest annual turnover of Spyre Therapeutics is USD 886k
What is the latest annual profit for Spyre Therapeutics?
The latest annual profit of Spyre Therapeutics is USD -338.79M
What is the registered address of Spyre Therapeutics?
The registered address for Spyre Therapeutics is 1521 CONCORD PIKE, SUITE 201, NEW CASTLE, WILMINGTON, DELAWARE, 19803
What is the Spyre Therapeutics website address?
The website address for Spyre Therapeutics is www.spyre.com
Which industry sector does Spyre Therapeutics operate in?
Spyre Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

ムーバー

すべて表示
  • 出来高
  • 値上がり率
  • 値下がり率
銘柄コード株価出来高
MYSZMy Size Inc
US$ 4.2001
(211.12%)
121.03M
NVNINVNI Group Ltd
US$ 8.26
(209.36%)
78.06M
TPICTPI Composites Inc
US$ 2.45
(100.82%)
34M
ICGIntchains Group Ltd
US$ 8.77
(88.60%)
527.94k
HSDTHelius Medical Technologies Inc
US$ 0.884851
(84.34%)
121.95M
CYNCYNGN Inc
US$ 0.4603
(-71.41%)
27.5M
MTEMMolecular Templates Inc
US$ 0.1502
(-57.09%)
8.63M
PRFXPainReform Ltd
US$ 5.15
(-53.85%)
2.84M
GALTGalectin Therapeutics Inc
US$ 1.03
(-48.50%)
8.58M
BCABBioAtla Inc
US$ 0.6923
(-41.82%)
5.96M
EDBLEdible Garden AG Inc
US$ 0.24
(65.06%)
354.33M
NVDANVIDIA Corporation
US$ 134.70
(3.08%)
310.19M
APTOAptose Biosciences Inc
US$ 0.28
(64.51%)
306.25M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0.606999
(6.49%)
293.22M
PLTRPalantir Technologies Inc
US$ 80.55
(8.54%)
281.23M

SYRE Discussion

投稿を表示

最近閲覧した銘柄

NASDAQ
SYRE
Spyre Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有